Japan Lifeline Announces Results of Acquisition of Own Shares
(Acquisition of Own Shares Under the Provisions of the Articles of Incorporation Pursuant to the
Provisions of Article 165, Paragraph (2) of the Companies Act)
Japan Lifeline Co., Ltd. ("the Company") announced today the results of the acquisition of own shares pursuant to the provisions of Article 156 of the Companies Act, as applied by replacing the relevant terms pursuant to the provisions of Article 165, paragraph (3) of the same Act.
(1)
Class of shares acquired
: Common shares of the Company
(2)
Total number of shares acquired
: 297,700 shares
(3)
Total amount of shares
: 315,498,996yen
acquisition costs
(4)
Acquisition period
: From May 11, 2023 to May 31, 2023
(5)
Acquisition method
: Market purchase on the Tokyo Stock Exchange
(Reference)
1. Details of the resolution regarding the acquisition of own shares at the Board of Directors meeting held on May 10, 2023
(1)
Class of shares to be
: Common shares of the Company
acquired
(2)
Total number of shares to
: 3,000,000 shares (maximum)
be acquired
(3.9% of the total number of shares issued excluding own shares)
(3)
Total amount of shares
: 4,000,000,000 yen (maximum)
acquisition costs
(4)
Acquisition period
: May 11, 2023 to February 29, 2024
(5)
Acquisition method
: Market purchase on the Tokyo Stock Exchange
2. Cumulative total of own shares acquired up to May 31, 2023 based on the above resolution
(1)
Total number of shares
: 297,700 shares
acquired
(2)
Total amount of shares
: 315,498,996 yen
acquisition costs
Attachments
Original Link
Original Document
Permalink
Disclaimer
JLL - Japan Lifeline Co. Ltd. published this content on 01 June 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 June 2023 06:15:23 UTC.
Japan Lifeline Co., Ltd. is a Japan-based company mainly engaged in the import, manufacture and sale of cardiac circulators and other medical devices. The Company is mainly engaged in the production of rhythm devices, electrophysiological (EP) and ablations, surgical products and intervention products. The rhythm devices include cardiac pacemakers, implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D) and other rhythm devices. The EP and ablations include EP catheters for cardiac arrhythmia examination, ablation catheters for arrhythmia treatment and other EP and ablations. The surgical products include prosthetic heart valves and annuloplasty rings for heart disease surgical treatment, vascular grafts, open stent grafts and stent grafts for aortic disease treatment, as well as other surgical products. The intervention products include balloon catheters, guide wires, penetration catheters and other intervention products.
JAPAN LIFELINE CO., LTD. 
